Log in

NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Forecast & News

$46.79
+0.05 (+0.11 %)
(As of 02/20/2020 05:33 AM ET)
Today's Range
$46.56
Now: $46.79
$46.93
50-Day Range
$46.11
MA: $46.79
$47.15
52-Week Range
$18.06
Now: $46.79
$47.55
Volume1.02 million shs
Average Volume878,027 shs
Market Capitalization$2.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.50 million
Book Value$4.92 per share

Profitability

Net Income$-64,940,000.00

Miscellaneous

Employees72
Market Cap$2.21 billion
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.


Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.05. The business earned $3 million during the quarter. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

11 equities research analysts have issued 12 month price objectives for Ra Pharmaceuticals' stock. Their forecasts range from $42.00 to $49.00. On average, they expect Ra Pharmaceuticals' share price to reach $47.50 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View Analyst Price Targets for Ra Pharmaceuticals.

What is the consensus analysts' recommendation for Ra Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ra Pharmaceuticals in the last year. There are currently 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ra Pharmaceuticals.

Has Ra Pharmaceuticals been receiving favorable news coverage?

Media stories about RARX stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ra Pharmaceuticals earned a daily sentiment score of -4.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Ra Pharmaceuticals.

Are investors shorting Ra Pharmaceuticals?

Ra Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 7,960,000 shares, an increase of 45.0% from the January 15th total of 5,490,000 shares. Based on an average daily trading volume, of 762,900 shares, the days-to-cover ratio is currently 10.4 days. Approximately 20.5% of the shares of the stock are sold short. View Ra Pharmaceuticals' Current Options Chain.

Who are some of Ra Pharmaceuticals' key competitors?

What other stocks do shareholders of Ra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Amarin (AMRN), Viking Therapeutics (VKTX), Fate Therapeutics (FATE), Immunomedics (IMMU), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE) and Advanced Micro Devices (AMD).

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Dr. Douglas A. Treco, Co-Founder, Pres, CEO & Director (Age 61)
  • Mr. David C. Lubner, Exec. VP & CFO (Age 55)
  • Dr. Ramin Farzaneh-Far, Chief Medical Officer (Age 42)
  • Mr. Alonso Ricardo, Chief Technology & Innovation Officer and Head of Research
  • Dr. Simon Read, Chief Scientific Officer (Age 48)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Who are Ra Pharmaceuticals' major shareholders?

Ra Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include CNH Partners LLC (4.04%), Magnetar Financial LLC (3.90%), Citigroup Inc. (3.70%), State Street Corp (3.47%), Farallon Capital Management LLC (2.52%) and ARP Americas LP (2.13%). Company insiders that own Ra Pharmaceuticals stock include Alonso Ricardo, Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp, Rajeev M Shah, Ramin Farzaneh-Far and Simon Read. View Institutional Ownership Trends for Ra Pharmaceuticals.

Which major investors are selling Ra Pharmaceuticals stock?

RARX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Eagle Asset Management Inc., Alliancebernstein L.P., UBS Asset Management Americas Inc., UBS Group AG, SG Americas Securities LLC, Rafferty Asset Management LLC and Bank of New York Mellon Corp. Company insiders that have sold Ra Pharmaceuticals company stock in the last year include Alonso Ricardo, Ramin Farzaneh-Far and Simon Read. View Insider Buying and Selling for Ra Pharmaceuticals.

Which major investors are buying Ra Pharmaceuticals stock?

RARX stock was bought by a variety of institutional investors in the last quarter, including CNH Partners LLC, Magnetar Financial LLC, Citigroup Inc., Farallon Capital Management LLC, ARP Americas LP, Gabelli Funds LLC, Renaissance Technologies LLC and Credit Suisse AG. Company insiders that have bought Ra Pharmaceuticals stock in the last two years include Enterprise Associates 13 L New, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Ra Pharmaceuticals.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $46.79.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $2.21 billion and generates $2.50 million in revenue each year. The company earns $-64,940,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Ra Pharmaceuticals employs 72 workers across the globe.View Additional Information About Ra Pharmaceuticals.

What is Ra Pharmaceuticals' official website?

The official website for Ra Pharmaceuticals is http://www.rapharma.com/.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (NASDAQ RARX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  480
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: What is a stock split?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel